Research progress on targets of rapid acting antidepressants
Depression is a chronic recurrent mental illness,and traditional antidepressants usually require several weeks of continuous use to achieve significant therapeutic effects.The launch of N-methyl-D-aspartate receptor antagonist ketamine has opened up a new perspective for the development of rapid acting antidepressants.Cholinergic receptor blocker scopolamine and 5-HT2A receptor agonist psilocybine have also shown potential for rapid antidepressant effects.This article summarizes the pharmacological target of rapid acting antidepressants glutamic acid rapid acting antidepressants,cholinergic receptor antagonists,and 5-HT2A receptor agonists(hallucinogens),analyzes possible strategies for new targets,with the aim of providing insights for future research on antidepressants.
NETL
NSTL
万方数据
